Clinical trials: CtDNA
Colorectal Cancer
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization.
- Trial name
- ECLIPSE (NCT04136002)
- Where
- 271 sites in United States
- Volunteers
- 44,467 people, healthy volunteers welcome
- Sponsor
- Guardant Health, Inc.
Lung Cancer
Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study
Despite scientific evidence, use of liquid biopsy (LB) in diagnosis and monitoring of lung cancer (LC) is limited since it requires major changes in diagnostic and care pathways.
- Trial name
- LM2 (NCT06105177)
- Where
- 5 sites in Netherlands
- Volunteers
- 800 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Colorectal Cancer
Circulating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study
In clinical practice, there are currently no biomarkers that can guide colorectal cancer treatment in the primary and curative setting.
- Trial name
- CITCCA (NCT04726800)
- Where
- 8 sites in Norway, Sweden
- Volunteers
- 300 people
- Sponsor
- Anna Martling
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02245100
- Testing
- Cytology specimen, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Advanced NSCLC, Circulating Tumor Cells
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation
- Conditions
- Advanced NSCLC, Circulating Tumor Cells, Circulating Tumor DNA
- Trial name
- NCT04229121
- Testing
- nonintervention
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
The BILLIONSTARS study is a prospective, single arm observational study inviting patients diagnosed with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) who are to be recommended locoregional intervention by surgery…
- Trial name
- BILLIONSTARS (NCT06877637)
- Where
- 3 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Region Skane
Circulating Tumor DNA, Cancer
Concordance Between ctDNA Assay and FoundationOne
Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has…
- Conditions
- Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing
- Trial name
- NCT02620527
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Foundation Medicine
Triple Negative Breast Cancer
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients
c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA) surveillance component and a therapeutic component.
- Trial name
- c-TRAK-TN (NCT03145961)
- Testing
- Pembrolizumab
- Where
- 17 sites in United Kingdom
- Volunteers
- 208 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
The study aims to explore the prevalence of EGFR mutations assessed with ctDNA samples in advanced NSCLC, who had received ≤ 1 prior systemic chemotherapy regimens.
- Trial name
- NCT02623257
- Testing
- mutation detection, ARMS, ctDNA analysis
- Where
- China
- Volunteers
- 1,055 people
- Sponsor
- First People's Hospital of Hangzhou
Colon Cancer
ctDNA and TEP Levels in Colon Cancer
This interventional cohort study will evaluate circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) as blood-based biomarkers in adults with stage III colon cancer who are planned to receive neoadjuvant systemic…
- Trial name
- NCT07701408
- Testing
- Additional Peripheral Venous Blood Sampling for ctDNA and TEP Biomarker Analysis
- Where
- Slovenia
- Volunteers
- 80 people
- Sponsor
- Institute of Oncology Ljubljana
Metastatic Breast Cancer, Circulating Tumor DNA
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.
- Conditions
- Metastatic Breast Cancer, Circulating Tumor DNA, Gene Abnormality
- Trial name
- ACTDNAGLT (NCT05427617)
- Testing
- Control group, Case group
- Volunteers
- 223 people
- Sponsor
- Hunan Cancer Hospital
Muscle-invasive Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are…
- Trial name
- IMvigor011 (NCT04660344)
- Testing
- Atezolizumab, Signatera
- Where
- 141 sites in United States, Argentina and 21 more
- Volunteers
- 761 people
- Sponsor
- Hoffmann-La Roche
Metastatic Cancer, Foregut Carcinoid Tumor
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
This study is designed for participants who have cancer of the upper gastrointestinal (GI) tract such as cancer of the esophagus, stomach, duodenum (the initial portion of your small intestine), pancreas, bile duct…
- Conditions
- Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma, Gallbladder Adenocarcinoma
- Trial name
- NCT04931420
- Testing
- Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), Lobectomy
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Chicago
Gastric / Gastroesophageal Junction Adenocarcinoma
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
For locally advanced gastric adenocarcinoma/esophagogastric junction adenocarcinoma, the currently recommended treatment strategy per clinical guidelines is radical gastrectomy combined with perioperative therapy (including…
- Trial name
- MRD-ATLAS-III (NCT07508956)
- Testing
- Standard neoadjuvant therapy: Chemotherapy/Targeted Therapy/Immunotherapy, Radical gastrectomy, Standard adjuvant therapy: Chemotherapy/Targeted Therapy/Immunotherapy
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Shanghai Zhongshan Hospital
BRAF V600E Mutation
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with…
- Trial name
- NCT06610682
- Testing
- Plixorafenib, Retifanlimab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Melanoma
Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma
The advent of immune ICI has remarkably improved survival in advanced melanoma patients in the last decade. Long term responders following 2 years of treatment with immunotherapy go on to surveillance with frequent radiological…
- Trial name
- PerceIVe (NCT06710093)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Breast Cancer (HR+/ HER2-)
Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer
This prospective observational study aims to evaluate the prognostic value of molecular imaging biomarkers derived from baseline [18F]FES and [18F]FDG PET/CT for progression-free survival in patients with estrogen receptor…
- Trial name
- NCT07867925
- Testing
- [18F] FES
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Unresectable Metastatic Melanoma
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable…
- Trial name
- BRAF SENS (NCT07870265)
- Testing
- Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripheral Blood Sampling for Liquid Biopsy
- Where
- Czechia
- Volunteers
- 17 people
- Sponsor
- Masaryk Memorial Cancer Institute
Ovarian Neoplasms, Ovary Cancer
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy. We hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for…
- Conditions
- Ovarian Neoplasms, Ovary Cancer, Ovarian Cysts
- Trial name
- NCT05763511
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- University of Aarhus
Colorectal Adenoma, Colorectal Cancer
Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence
To evaluate the accuracy and effectiveness of a novel screening method based on plasma multi-omics combining with artificial intelligence in a large prospective cohort for the detection of colorectal cancer and advanced adenomas.
- Trial name
- RECOMMEND (NCT05587452)
- Testing
- Colonoscopy, Test of ctDNA methylation, Test of characteristics of ctDNA fragment
- Where
- 5 sites in China
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences